Recruiting

GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound

An Observational Study to Examine Non-inferiority of the Standard ASA Fasting Guidelines Versus 24-hour Clear Liquid Diet for Gastric Volume in Patients Taking GLP-1 Agonists

Lead sponsor

Medical University of South Carolina

Assets

Dulaglutide / Exenatide / Liraglutide / Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

150

Study population

Eligibility highlights

Primary endpoint

•Pre-operative gastric volume

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07251803

Org study IDPro00147318

Timeline

Milestones

Study first posted2025-11-26actual

Study start2026-02-03actual

Last update posted2026-02-25actual

Primary completion2026-12-31estimated

Study completion2026-12-31estimated

Assets

Investigational agents

Dulaglutide Exenatide Liraglutide Semaglutide Tirzepatide

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

This study will consist of patients who have taken a GLP-1 or GLP-GIP agonist medication within the past 30 days, and are scheduled for either an elective surgery and appropriately NPO for at least 8 hours prior, or scheduled for elective colonoscopy and have been on a clear liquid diet for at least 24 hours prior.

Inclusion criteria

•Age 18+

•Have taken a GLP-1 or GLP-GIP agonist medication within the past 30 days

•ASA Physical Classification Status 1-3

•Fall into one of the following groups:

1. Scheduled elective surgery and meet ASA fasting guidelines (NPO for at least 8 hours prior)

2. Scheduled elective colonoscopy and have been on a clear liquid diet for at least 24 hours prior

Exclusion criteria

•Previous gastric or esophageal surgery

•Abnormal gastric anatomy

•Pregnancy

•Unable to provide written, informed consent

•Non-English speaking

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Weight & body composition

1 endpoint

Primary/protocol endpoint

Pre-operative gastric volume per unit of weight (ml/kg) as assessed by gastric ultrasound.

Time frame:From enrollment until completion of pre-operative gastric ultrasound (typically within 3 hours of scheduled procedure).

descriptive

Other clinical outcomes

3 endpoints

Secondary/protocol endpoint

Incidence of full stomach on gastric ultrasound assessment

Time frame:From time of enrollment until the start of surgery, up to 24 hours.

event count, event

Secondary/protocol endpoint

Incidence of regurgitation under anesthesia

Time frame:From induction of anesthesia until end of surgery (up to 8 hours).

event count, event

Secondary/protocol endpoint

Incidence of change in anesthetic management based on stomach contents

Time frame:Assessed at enrollment and during gastric ultrasound (within 3 hours of scheduled procedure).

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Perlas antral grade

Time frame:From enrollment until completion of gastric ultrasound (within 3 hours of scheduled procedure).

descriptive

Secondary/protocol endpoint/low confidence

Differences in "high risk GLP-1" vs "low risk GLP-1"

Time frame:assessed at time of enrollment from the past 30 days until completion of gastric ultrasound

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.